PL2862860T3 - Związki 1,3-oksazolidyny, lub 1,3-oksazynanu jako antagoniści receptora oreksyny - Google Patents
Związki 1,3-oksazolidyny, lub 1,3-oksazynanu jako antagoniści receptora oreksynyInfo
- Publication number
- PL2862860T3 PL2862860T3 PL13804876T PL13804876T PL2862860T3 PL 2862860 T3 PL2862860 T3 PL 2862860T3 PL 13804876 T PL13804876 T PL 13804876T PL 13804876 T PL13804876 T PL 13804876T PL 2862860 T3 PL2862860 T3 PL 2862860T3
- Authority
- PL
- Poland
- Prior art keywords
- oxazinane
- oxazolidine
- compounds
- receptor antagonists
- orexin receptor
- Prior art date
Links
- LQPOOAJESJYDLS-UHFFFAOYSA-N 1,3-oxazinane Chemical class C1CNCOC1 LQPOOAJESJYDLS-UHFFFAOYSA-N 0.000 title 1
- 229940123730 Orexin receptor antagonist Drugs 0.000 title 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012135277 | 2012-06-15 | ||
| EP13804876.4A EP2862860B1 (en) | 2012-06-15 | 2013-06-13 | 1,3-oxazolidine or 1,3-oxazinane compounds as orexin receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2862860T3 true PL2862860T3 (pl) | 2017-06-30 |
Family
ID=49758285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13804876T PL2862860T3 (pl) | 2012-06-15 | 2013-06-13 | Związki 1,3-oksazolidyny, lub 1,3-oksazynanu jako antagoniści receptora oreksyny |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US9266870B2 (en:Method) |
| EP (1) | EP2862860B1 (en:Method) |
| JP (1) | JP5896319B2 (en:Method) |
| KR (1) | KR102098977B1 (en:Method) |
| CN (1) | CN104350053B (en:Method) |
| AU (1) | AU2013275210B2 (en:Method) |
| BR (1) | BR112014031360B1 (en:Method) |
| CA (1) | CA2876253C (en:Method) |
| CY (1) | CY1118848T1 (en:Method) |
| DK (1) | DK2862860T3 (en:Method) |
| ES (1) | ES2613663T3 (en:Method) |
| HR (1) | HRP20161797T1 (en:Method) |
| HU (1) | HUE031538T2 (en:Method) |
| IL (1) | IL236140A (en:Method) |
| IN (1) | IN2014DN10490A (en:Method) |
| LT (1) | LT2862860T (en:Method) |
| ME (1) | ME02606B (en:Method) |
| MX (1) | MX355660B (en:Method) |
| MY (1) | MY171464A (en:Method) |
| NZ (1) | NZ702647A (en:Method) |
| PH (1) | PH12014502750B1 (en:Method) |
| PL (1) | PL2862860T3 (en:Method) |
| PT (1) | PT2862860T (en:Method) |
| RS (1) | RS55675B1 (en:Method) |
| RU (1) | RU2639869C2 (en:Method) |
| SG (1) | SG11201408327XA (en:Method) |
| SI (1) | SI2862860T1 (en:Method) |
| SM (1) | SMT201700141T1 (en:Method) |
| TW (1) | TWI583683B (en:Method) |
| WO (1) | WO2013187467A1 (en:Method) |
| ZA (1) | ZA201409168B (en:Method) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ME02437B (me) | 2009-10-23 | 2016-09-20 | Janssen Pharmaceutica Nv | Disupstituirani oktahidropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| JP5907310B2 (ja) * | 2013-12-13 | 2016-04-26 | 大正製薬株式会社 | オキサジナン化合物の結晶形及びその製造方法 |
| CN104370755B (zh) * | 2014-08-18 | 2017-04-12 | 江西隆莱生物制药有限公司 | 一种光学活性的3‑氨基丁醇和3‑氨基丁酸的制备方法 |
| JP2018188364A (ja) * | 2015-10-02 | 2018-11-29 | 大正製薬株式会社 | 複素芳香環誘導体 |
| IL288321B2 (en) | 2016-03-10 | 2025-08-01 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| CN108129426B (zh) * | 2016-12-01 | 2021-06-29 | 中国科学院大连化学物理研究所 | 一种2,5-二氰基呋喃催化加氢合成2,5-二甲胺基呋喃的方法 |
| JOP20190156B1 (ar) * | 2016-12-23 | 2023-09-17 | Bayer Pharma AG | أميدات عطرية لحمض الكربوكسيليك بصفتها مضادات لمستقبلة البراديكينين b1 |
| JP7178002B2 (ja) * | 2017-07-13 | 2022-11-25 | 大正製薬株式会社 | （２ｓ）－２－［（１ｈ－ピラゾール－１－イル）メチル］－１，３－オキサジナン誘導体の製造方法 |
| CN110967321A (zh) * | 2018-09-29 | 2020-04-07 | 泰州医药城国科化物生物医药科技有限公司 | 一种用于均一体系细胞荧光检测钙流方法 |
| CN115968403A (zh) | 2020-05-22 | 2023-04-14 | 纽卫制药有限公司 | 用于治疗脑白质营养不良的vlp |
| CN113336655A (zh) * | 2020-12-30 | 2021-09-03 | 江西迪赛诺制药有限公司 | 一种(r)-3-氨基丁醇的制备方法 |
| CN116925022B (zh) * | 2023-07-06 | 2025-08-01 | 江苏信和生物医药有限公司 | 一种(s)-5-烯丙基-2-氧杂双环[3.3.0]辛-8-烯的制备方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0115862D0 (en) * | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| US7169744B2 (en) * | 2002-06-06 | 2007-01-30 | Procter & Gamble Company | Organic catalyst with enhanced solubility |
| JP5205274B2 (ja) * | 2006-11-22 | 2013-06-05 | 日本農薬株式会社 | 新規なピラゾール誘導体、有害生物防除剤及びその使用方法 |
| WO2008108991A1 (en) * | 2007-03-02 | 2008-09-12 | Merck & Co., Inc. | Bipyridine carboxamide orexin receptor antagonists |
| CN101679366B (zh) * | 2007-05-23 | 2013-08-07 | 默沙东公司 | 吡啶基哌啶食欲素受体拮抗剂 |
| AU2008284268A1 (en) * | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| WO2010038200A1 (en) * | 2008-10-01 | 2010-04-08 | Actelion Pharmaceuticals Ltd | Oxazolidine compounds as orexin receptor antagonists |
| WO2010044054A1 (en) * | 2008-10-14 | 2010-04-22 | Actelion Pharmaceuticals Ltd | Phenethylamide derivatives and their heterocyclic analogues |
| WO2010048013A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted morpholine orexin receptor antagonists |
| US8399494B2 (en) | 2008-10-30 | 2013-03-19 | Merck Sharp & Dohme Corp. | 2,5-disubstituted phenyl carboxamide orexin receptor antagonists |
| JP5635991B2 (ja) | 2008-10-30 | 2014-12-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | イソニコチンアミドオレキシン受容体アンタゴニスト |
| TW201307320A (zh) * | 2010-12-17 | 2013-02-16 | 大正製藥股份有限公司 | 吡唑衍生物 |
| JPWO2012153729A1 (ja) | 2011-05-10 | 2014-07-31 | 大正製薬株式会社 | ヘテロ芳香環誘導体 |
-
2013
- 2013-06-13 IN IN10490DEN2014 patent/IN2014DN10490A/en unknown
- 2013-06-13 DK DK13804876.4T patent/DK2862860T3/en active
- 2013-06-13 JP JP2014521401A patent/JP5896319B2/ja active Active
- 2013-06-13 CN CN201380031372.4A patent/CN104350053B/zh active Active
- 2013-06-13 ES ES13804876.4T patent/ES2613663T3/es active Active
- 2013-06-13 PL PL13804876T patent/PL2862860T3/pl unknown
- 2013-06-13 MX MX2014015077A patent/MX355660B/es active IP Right Grant
- 2013-06-13 PT PT138048764T patent/PT2862860T/pt unknown
- 2013-06-13 BR BR112014031360-1A patent/BR112014031360B1/pt active IP Right Grant
- 2013-06-13 ME MEP-2017-34A patent/ME02606B/me unknown
- 2013-06-13 HU HUE13804876A patent/HUE031538T2/en unknown
- 2013-06-13 RU RU2015101102A patent/RU2639869C2/ru active
- 2013-06-13 SM SM20170141T patent/SMT201700141T1/it unknown
- 2013-06-13 CA CA2876253A patent/CA2876253C/en active Active
- 2013-06-13 SI SI201330457A patent/SI2862860T1/sl unknown
- 2013-06-13 RS RS20170123A patent/RS55675B1/sr unknown
- 2013-06-13 EP EP13804876.4A patent/EP2862860B1/en active Active
- 2013-06-13 NZ NZ702647A patent/NZ702647A/en unknown
- 2013-06-13 MY MYPI2014703693A patent/MY171464A/en unknown
- 2013-06-13 SG SG11201408327XA patent/SG11201408327XA/en unknown
- 2013-06-13 US US14/407,353 patent/US9266870B2/en active Active
- 2013-06-13 WO PCT/JP2013/066322 patent/WO2013187467A1/ja not_active Ceased
- 2013-06-13 HR HRP20161797TT patent/HRP20161797T1/hr unknown
- 2013-06-13 LT LTEP13804876.4T patent/LT2862860T/lt unknown
- 2013-06-13 AU AU2013275210A patent/AU2013275210B2/en active Active
- 2013-06-13 KR KR1020147035124A patent/KR102098977B1/ko active Active
- 2013-06-14 TW TW102121127A patent/TWI583683B/zh active
-
2014
- 2014-12-08 IL IL236140A patent/IL236140A/en active IP Right Grant
- 2014-12-09 PH PH12014502750A patent/PH12014502750B1/en unknown
- 2014-12-12 ZA ZA2014/09168A patent/ZA201409168B/en unknown
-
2017
- 2017-03-08 CY CY20171100300T patent/CY1118848T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT2862860T (lt) | 1,3-oksazolidino arba 1,3-oksazinano junginiai kaip oreksino receptoriaus antagonistai | |
| PL2938695T3 (pl) | Kompozycja zawierająca 2,3,3,3-tetrafluoropropen | |
| AP3391A (en) | 2-Amino-4-arylthiazole compounds as TROA1 antagonists | |
| IL236087A0 (en) | n–aryltriazole compounds as lpar antagonists | |
| IL236088A0 (en) | n-Alkyltriazole compounds as lpar antagonists | |
| IL236898A0 (en) | 2, 3- benzodiazepines | |
| IL233592A0 (en) | p2x4 receptor antagonist | |
| IL238974A0 (en) | cxcr7 antagonists | |
| IL234025A0 (en) | Transduced prolines/piperidines as orexin receptor antagonists | |
| ZA201500781B (en) | 5-ht3 receptor antagonists | |
| EP2699091A4 (en) | 2 ', 6'-dioxo-3'-deutero-PIPERIDIN-3-YL-isoindoline COMPOUNDS | |
| ZA201306229B (en) | Substituted 4-aryl-n-phenyl-1,3,5-triazin-2- amines | |
| ZA201405959B (en) | Novel neurokinin 1 receptor antagonist compounds | |
| IL235681A0 (en) | 5- amino [1, 4] thiazines as 1 bace inhibitors | |
| ZA201503682B (en) | 3,3'-dinitro-5,5'-bistriazole-1,1'-diol | |
| IL237538A0 (en) | Amphiphilic compounds, their preparations and uses | |
| IL237539A0 (en) | Amphiphilic compounds, their preparations and uses | |
| GB201213698D0 (en) | Receptor antagonists II | |
| GB201213699D0 (en) | Receptor antagonists II | |
| GB201220558D0 (en) | Novel compounds 1 | |
| GB201206730D0 (en) | Novel compounds 1 | |
| GB201013708D0 (en) | [1,4]-Benzodiazepines as vasopressin v2 receptor antagonists |